Want to see SCNI full AI Analyst Report?
Top Page
Scinai Immunotherapeutics
(NASDAQ:SCNI)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.51
▼(-82.20% Downside)
Action:Reiterated
Date:10/22/26
SCNI scores low primarily due to weak financial performance (ongoing losses and cash burn) and bearish technicals (price far below major moving averages with negative momentum). The earnings call adds some support via improving commercial traction and revenue targets, but near-term liquidity and execution/dilution risks remain prominent; valuation signals are not meaningful given the provided P/E and lack of dividend.
Positive Factors
CDMO Contract Growth
The larger contracted backlog improves revenue visibility and supports higher utilization across Scinai’s CDMO operations. The agreement also provides a foundation for customer payments and future project phases, strengthening the company’s commercial platform over the next several quarters.
Negative Factors
Persistent Operating Losses
The expanded CDMO footprint currently carries costs well above the revenue generated, leaving the core business materially unprofitable. Until utilization improves, recurring operating losses can absorb capital and limit Scinai’s ability to fund development internally.
Read all positive and negative factors
Positive Factors
Negative Factors
CDMO Contract Growth
The larger contracted backlog improves revenue visibility and supports higher utilization across Scinai’s CDMO operations. The agreement also provides a foundation for customer payments and future project phases, strengthening the company’s commercial platform over the next several quarters.
Read all positive factors
Scinai Immunotherapeutics (SCNI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$302.68K
Dividend YieldN/A
Average Volume (3M)2.96M
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue Growth30.12%
EPS Growth-165.46%
CountryUS
Employees45
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-62161.60
Shares Outstanding706,586
10 Day Avg. Volume6,814,307
30 Day Avg. Volume2,963,118
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)1.27
P/FCF Ratio-0.27
Enterprise Value/Market Cap25.75
Enterprise Value/Revenue5.22
Enterprise Value/Gross Profit-2.07
Enterprise Value/Ebitda-1.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Scinai Immunotherapeutics Business Overview & Revenue Model
Company Description
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a rang...
How the Company Makes Money
Publicly available, company-specific detail on Scinai Immunotherapeutics’ current revenue model and recurring revenue streams is not available in the information provided. null...
Scinai Immunotherapeutics Earnings Call Summary
Earnings Call Date:Aug 20, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Dec 02, 2026
Earnings Call Sentiment Neutral
The call conveys a constructive strategic story: the Recipharm acquisition materially expanded Scinai's capabilities and produced early commercial traction (committed orders, invoicing and a U.S. engagement with ~$650k in post-quarter cash). However, near-term financials show meaningful operating and gross losses and a modest cash balance (~$2.85M), leaving the company reliant on successful conversion of orders, utilization improvements and additional funding. Management emphasizes disciplined R&D spending, use of non-dilutive funding and selective use of the $15M SEPA. Given the balance of promising commercial/strategic progress against short-term liquidity and operating loss challenges, the tone is cautiously optimistic but pragmatic.Positive Updates
Revenue Growth Year-over-Year
Reported revenue for H1 2026 was approximately $949,000 versus $773,000 in H1 2025, an increase of ~22.8% year-over-year, indicating early commercial traction following the acquisition.
Negative Updates
Operating and Gross Losses
Despite the accounting gain, underlying operations produced a gross loss of approximately $2.37M and an operating loss of approximately $4.6M for H1 2026, reflecting fixed/semi-fixed costs from the expanded CDMO footprint before utilization ramped.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth Year-over-Year
Reported revenue for H1 2026 was approximately $949,000 versus $773,000 in H1 2025, an increase of ~22.8% year-over-year, indicating early commercial traction following the acquisition.
Read all positive updates
Company Guidance
Management's guidance is focused on commercial execution and capital discipline: they are pursuing approximately $5.0M of CDMO revenue for 2026 and aim to convert ~$3.1M of committed customer orders (≈$1.6M Yavne / ≈$1.5M Jerusalem; ≈$2.1M invoiced as of Aug 10 and ≈$1.0M signed but not yet invoiced) into recognized revenue and higher utilization across Jerusalem and Yavne; liquidity stood at ≈$2.85M cash and restricted cash as of June 30, they received ≈$650k in cash/advances after June 30 from a U.S. clinical manufacturing engagement, and H1 results showed revenue ≈$949k (vs ≈$773k H1 2025), gross loss ≈$2.37M, operating loss ≈$4.6M, and a noncash bargain purchase gain ≈$6.4M that produced net income ≈$1.57M; management plans to emphasize repeat business, non-dilutive funding and selective use of the existing $15M SEPA (post‑effective amendment; advances priced at 97% of VWAP) while prioritizing R&D spend.Scinai Immunotherapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.49M | 1.31M | 658.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.77M | -2.65M | -580.00K | 0.00 | 0.00 | -747.65K |
| EBITDA | -6.66M | -6.53M | -6.99M | -2.19M | -5.23M | -10.32M |
| Net Income | -2.64M | -8.31M | 4.80M | -6.50M | -5.80M | -12.38M |
Balance Sheet | ||||||
| Total Assets | 17.17M | 11.63M | 13.45M | 17.47M | 27.07M | 32.04M |
| Cash, Cash Equivalents and Short-Term Investments | 2.85M | 1.66M | 1.96M | 4.87M | 14.07M | 17.37M |
| Total Debt | 3.58M | 2.27M | 2.09M | 20.56M | 21.54M | 29.23M |
| Total Liabilities | 5.44M | 3.52M | 3.47M | 22.04M | 28.83M | 31.05M |
| Stockholders Equity | 11.73M | 8.10M | 9.98M | -4.57M | -1.76M | 982.00K |
Cash Flow | ||||||
| Free Cash Flow | -7.53M | -6.05M | -6.35M | -10.02M | -8.10M | -7.57M |
| Operating Cash Flow | -7.40M | -6.03M | -6.33M | -9.38M | -7.26M | -7.43M |
| Investing Cash Flow | 2.64M | -24.00K | -12.00K | -637.00K | -836.00K | -139.00K |
| Financing Cash Flow | 6.53M | 5.77M | 3.44M | 1.09M | 6.78M | 21.43M |
Scinai Immunotherapeutics Technical Analysis
Negative
2.87
Price Trends
1.66
Negative
2.21
Negative
4.58
Negative
Market Momentum
-0.32
Positive
24.08
Positive
3.20
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCNI, the sentiment is Negative. The current price of 2.87 is above the 20-day moving average (MA) of 0.96, above the 50-day MA of 1.66, and below the 200-day MA of 4.58, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 24.08 is Positive, neither overbought nor oversold. The STOCH value of 3.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCNI.
Scinai Immunotherapeutics Risk Analysis
Scinai Immunotherapeutics disclosed 78 risk factors in its most recent earnings report. Scinai Immunotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scinai Immunotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
SCNI
Scinai Immunotherapeutics
0.53
-13.97
-96.32%
GTBP
GT Biopharma
5.51
-9.42
-63.09%
ADTX
Aditxt
0.04
-2,794.68
-100.00%
CERO
CERo Therapeutics Holdings
0.01
-1.78
-99.44%
PBM
Psyence Biomedical
3.40
-17.16
-83.46%
CDT
CDT Equity
0.08
-18,124.92
-100.00%
Scinai Immunotherapeutics Corporate Events
Scinai Immunotherapeutics Extends Cash Runway on New CDMO Deal and October Financing
Oct 20, 2026
On October 20, 2026, Scinai Immunotherapeutics reported that a new CDMO agreement with a U.S.-based Nasdaq-listed biopharmaceutical client and recently completed equity financings have significantly expanded its contracted business and strengthene...
Scinai Immunotherapeutics Closes $4 Million Private Placement and Warrant Deal
Oct 16, 2026
On October 16, 2026, Scinai Immunotherapeutics closed a $4.0 million financing, combining a private placement of American Depositary Shares and an inducement for immediate exercise of existing warrants, which also generated new Series A-1 warrants...
Scinai Immunotherapeutics Secures $4 Million via Private Placement and Warrant Inducement
Oct 15, 2026
On October 13, 2026, Scinai Immunotherapeutics entered into a securities purchase agreement with an existing institutional life sciences investor for a private placement of 2,458,334 American Depositary Shares or pre-funded warrants, plus Series A...
Scinai Immunotherapeutics Secures $5.1 Million CDMO Deal, Tripling Committed Orders
Oct 13, 2026
Scinai Immunotherapeutics announced on October 13, 2026 that its subsidiary Scinai Biopharma Services has signed a definitive development and clinical manufacturing agreement worth approximately $5.1 million in committed base service fees with a U...
Scinai Immunotherapeutics Restores Nasdaq Minimum Bid Price Compliance
Sep 21, 2026
On September 21, 2026, Scinai Immunotherapeutics announced that Nasdaq has confirmed the company regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), closing a months-long listing risk. The decision follo...
Scinai Shifts Capital to NanoAb Platform and CDMO Growth After Ending PC111 Deal
Sep 8, 2026
On September 8, 2026, Scinai Immunotherapeutics announced it had allowed its option and license agreements with PinCell regarding the preclinical program PC111 to expire on August 31, 2026, ending its involvement without securing new funding. The ...
Scinai Highlights First-Half CDMO Expansion and Recipharm Israel Gain in August 2026 Update
Aug 26, 2026
In a business update released on August 24, 2026, Scinai Immunotherapeutics reported growing momentum in its CDMO arm, with committed customer orders reaching about $3.1 million as of August 16, 2026 and an expanded clinical manufacturing and CMC ...
Scinai Immunotherapeutics Sets 1-for-10 ADS Ratio Change to Support Nasdaq Compliance
Aug 19, 2026
On August 19, 2026, Scinai Immunotherapeutics announced that, effective August 21, 2026, it will change the ratio of its American Depositary Shares so that one ADS will represent 40,000 ordinary shares instead of 4,000, a move that functions as a ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.